1. Scrip
  2. >>Business
  3. >>Start-Ups & SMEs

Venture Funding Deals: ADC Therapeutics, Unity Biotech Raise $100m-Plus

 
• By Deanna Kamienski, Beth Allan, Maureen Riordan, and Steven Muntner

ADC Therapeutics and Unity Biotechnology close $100m-plus VC rounds, while Carrick comes close with a $95m debut. Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging biopharmaceutical companies that have received venture funding. This month’s column covers deals announced in September and October 2016.

Cancer company Achilles Therapeutics Ltd. has launched with a £13.2m ($16.9m) Series A round provided by CRT Pioneer Fund, UCL Technology Fund, and company founders Syncona LLP, Cancer Research UK’s Cancer Research Technology (CRT), UCL Business and the Francis Crick Institute. (Oct.)

Achilles will design cancer therapies using technology exclusively licensed from Cancer Research UK pertaining to truncal neo-antigens, which are protein markers present on all cancer cells but not on healthy cells, and unique to each patient and each cancer type. Truncal mutations occur in healthy cells before the cells divide and grow into cancer cells

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Start-Ups & SMEs

More from Business

Pharma Predicts Modest Impact From Tariffs, But It Depends On What Comes Next

 
• By Jessica Merrill

Drugmakers aren’t expecting a big financial hit from tariffs for now, but a report commissioned by PhRMA suggests the cost of pharma-sector tariffs could be steep.

OPPI’s Matai On Section 3(d) Of India’s Patent Regulations: Now’s The Time To Open Up

 
• By Anju Ghangurde

Anil Matai, director general, Organization of Pharmaceutical Producers of India, talks in this audio interview about the evolving intellectual property landscape in India post the 2024 amendments, including long-standing sticking points such as Section 3(d) of India’s patent regulations and innovator firms' experience of the Bolar provision. There’s also a "compelling reason" to consider regulatory data protection, he claims.

In Brief: Sanofi Gains €10bn From Opella Sale

 
• By Sushmita Panda

Sanofi sold a 50% stake in consumer health unit Opella for €10bn, backing its shift to prescription drugs and funding a €5bn buyback.